Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 ponatinib trial in refractory CML and Philadelphia chromosome-positive ALL
NL-OMON39645Phase 2Active, not recruiting
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ponatinib in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), sponsored by ARIAD Pharmaceuticals, Inc. Primary endpoints: Major cytogenetic response in chronic phase CML, Major hematologic response in accelerated phase CML and 1 more. Started Feb 2011; status: active, not recruiting.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON39645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39645.